Whitehawk Therapeutics has entered an option agreement with Hangzhou DAC to access CPT113 technology for up to five new antibody drug conjugate (ADC) cancer treatment programs. This agreement allows Whitehawk to select targets and antibodies while retaining global rights and control, aiming to submit Investigational New Drug applications within 12-24 months. The CPT113 technology, validated by external programs and enhanced by Whitehawk's proprietary bioconjugation process, supports improved ADC stability and therapeutic potential. Current Phase 1 trials for HWK-007 and HWK-016 are ongoing, with data expected in the first half of 2027, signaling strong pipeline growth and clinical advancement.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
